clinical trial · NCT07709715
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis
Light Chain (AL) AmyloidosisNXC-201Dara-CyBorD
brief summary
The purpose of this study is to evaluate the efficacy and safety of NXC-201 compared with Dara-CyBorD (daratumumab-cyclophosphamide-bortezomib-dexamethasone) in the treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.
started
Jan 1, 2027
primary completion
Dec 1, 2028
completion
Dec 1, 2032
last updated
Jul 16, 2026
official title
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis [NEXICART-3]
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol